Clinical features of autoimmune hepatitis patients with poor response to treatment
10.3760/cma.j.issn.1007-3418.2017.10.007
- VernacularTitle: 自身免疫性肝炎治疗应答不良患者的临床特点分析
- Author:
Hongwen ZHANG
1
;
Huimin LIU
;
Rui LIN
;
Lu ZHOU
;
Jie ZHANG
;
Wentian LIU
Author Information
1. Department of gastroenterology, The General Hospital of Tianjin Medical University Tianjin 300052, China
- Publication Type:Journal Article
- Keywords:
Hepatitis, autoimmune;
Liver cirrhosis;
Autoantibodies;
Therapy
- From:
Chinese Journal of Hepatology
2017;25(10):755-759
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features of autoimmune hepatitis (AIH) patients with poor response to treatment.
Methods:A total of 61 AIH patients were enrolled, among whom 49 (80.33%) achieved complete response (good response group) and 12 (19.67%) had incomplete response (poor response group). The two groups were compared in terms of clinical manifestations, laboratory markers, abdominal ultrasound findings, pathological features by liver biopsy, and response to treatment. Continuous data were expressed as mean ± standard deviation (x±s), and the t-test was used for comparison between groups; categorical data were expressed as rates or percentages, and the chi-square test was used for comparison between groups; a binary logistic regression analysis was used to determine influencing factors.
Results:Most patients were female in both groups, and there were no significant differences in sex ratio, mean age of onset, and general status including extrahepatic autoimmune disease between the two groups. Compared with the good response group, the poor response group had significantly higher levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase (ALP), total bilirubin, immunoglobulin G, and immunoglobulin M (P < 0.05). Compared with the good response group, the poor response group had a significantly higher positive rate of autoimmune antibodies except anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), antimitochondrial antibody (AMA), and AMA/M2 (75% vs 16.3%, P < 0.001), and there was a significant difference in the positive rate of gp210 antibody between the two groups (25% vs 0%, P < 0.01). There were significant differences between the poor response group and the good response group in the proportion of patients with liver cirrhosis (50.0 % vs 16.3%, P < 0.05) and splenomegaly (58.3% vs 22.4%, P < 0.05). The binary logistic regression analysis showed that a high serum level of ALP (odds ratio [OR] = 1.017, 95% confidence interval [CI] 1.001-1.033, P = 0.034), positive autoimmune antibodies except ANA, SMA, and AMA/M2 (OR = 70.842, 95% CI 2.132-2 354.371, P = 0.017), and liver cirrhosis (OR = 28.777, 95% CI 1.015-815.854, P = 0.049) were independent risk factors for initial treatment outcome.
Conclusion:A high serum level of ALP, positive autoimmune antibodies except ANA, SMA, and AMA/M2, and liver cirrhosis are closely associated with poor response in AIH patients.
